View All Documents & Correspondence
Pharmaceutical Composition Comprising A Quinazoline Compound
Abstract: The present invention has an object to provide a pharmaceutical composition for treating a cancer of colorectal cancer and/or lung cancer. The present inventors have studied about a compound that is useful as an active ingredient of a pharmaceutical composition for treating a cancer, and have found that a quinazoline compound has an excellent degradation- inducing action on a G12D mutant KRAS protein and a G12D mutant KRAS inhibition activity and that a pharmaceutical composition containing the compound as an active ingredient can be used as a therapeutic agent for a cancer, completing the present invention. The pharmaceutical composition of the present invention which contains a quinazoline compound or a salt thereof as an active ingredient can be used as a therapeutic agent for a cancer of colorectal cancer and/or lung cancer.
Notices, Deadlines & Correspondence
Patent Information
Applicants
ASTELLAS PHARMA INC.
Inventors
1. NAGASHIMA, Takeyuki
Specification
Documents
Application Documents
| # | Name | Date |
|---|---|---|
| 1 | 202447054925-STATEMENT OF UNDERTAKING (FORM 3) [18-07-2024(online)].pdf | 2024-07-18 |
| 2 | 202447054925-REQUEST FOR EXAMINATION (FORM-18) [18-07-2024(online)].pdf | 2024-07-18 |
| 3 | 202447054925-PROOF OF RIGHT [18-07-2024(online)].pdf | 2024-07-18 |
| 4 | 202447054925-PRIORITY DOCUMENTS [18-07-2024(online)].pdf | 2024-07-18 |
| 5 | 202447054925-FORM 18 [18-07-2024(online)].pdf | 2024-07-18 |
| 6 | 202447054925-FORM 1 [18-07-2024(online)].pdf | 2024-07-18 |
| 7 | 202447054925-DECLARATION OF INVENTORSHIP (FORM 5) [18-07-2024(online)].pdf | 2024-07-18 |
| 8 | 202447054925-COMPLETE SPECIFICATION [18-07-2024(online)].pdf | 2024-07-18 |
| 9 | 202447054925-FORM-26 [22-07-2024(online)].pdf | 2024-07-22 |
| 10 | 202447054925-FORM 3 [07-01-2025(online)].pdf | 2025-01-07 |